Sotiris Vandoros
Sotiris Vandoros
King's College London and Harvard University
Verified email at - Homepage
Cited by
Cited by
Have health trends worsened in Greece as a result of the financial crisis? A quasi-experimental approach
S Vandoros, P Hessel, T Leone, M Avendano
The European Journal of Public Health 23 (5), 727-731, 2013
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
P Kanavos, A Ferrario, S Vandoros, GF Anderson
Health affairs 32 (4), 753-761, 2013
Differences in costs of and access to pharmaceutical products in the EU
P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson
European Parliament, 2011
Reforms in the Greek pharmaceutical market during the financial crisis
S Vandoros, T Stargardt
Health policy 109 (1), 1-6, 2013
Excess mortality during the Covid-19 pandemic: Early evidence from England and Wales
S Vandoros
Social Science & Medicine 258, 113101, 2020
Determinants of branded prescription medicine prices in OECD countries
PG Kanavos, S Vandoros
Health economics, policy and law 6 (3), 337-367, 2011
Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium
P Kanavos, L Seeley, S Vandoros
LSE Health London School of Economics, 2009
The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
F Von der Schulenburg, S Vandoros, P Kanavos
Health economics review 1 (1), 1-8, 2011
The impact of the Great Recession on health-related risk factors, behaviour and outcomes in England
M Jofre-Bonet, V Serra-Sastre, S Vandoros
Social Science & Medicine 197, 213-225, 2018
The association between economic uncertainty and suicide in the short-run
S Vandoros, M Avendano, I Kawachi
Social Science & Medicine 220, 403-410, 2019
The differential impact of the financial crisis on health in Ireland and Greece: a quasi-experimental approach
P Hessel, S Vandoros, M Avendano
Public health 128 (10), 911-919, 2014
The generics paradox revisited: empirical evidence from regulated markets
S Vandoros, P Kanavos
Applied Economics 45 (22), 3230-3239, 2013
Competition in prescription drug markets: is parallel trade the answer?
P Kanavos, S Vandoros
Managerial and decision economics 31 (5), 325-338, 2010
Raising the bar for market authorisation of new drugs
H Naci, J Cylus, S Vandoros, A Sato, K Perampaladas
Bmj 345, 2012
Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP
P Kanavos, S Vandoros, P Garcia-Gonzalez
Globalization and health 5 (1), 1-13, 2009
The impact of bank competition and concentration on industrial growth
G Liu, A Mirzaei, S Vandoros
Economics Letters 124 (1), 60-63, 2014
Household expenditures for medicines and the role of free medicines in the Brazilian public health system
AD Bertoldi, AJD Barros, AL Camargo, PC Hallal, S Vandoros, A Wagner, ...
American journal of public health 101 (5), 916-921, 2011
Introduction and utilization of high priced HCV medicines across Europe; implications for the future
W de Bruijn, C Ibáñez, P Frisk, H Bak Pedersen, A Alkan, ...
Frontiers in pharmacology 7, 197, 2016
Greasy roads: the impact of bad financial news on road traffic accidents
S Vandoros, G Kavetsos, P Dolan
Risk analysis 34 (3), 556-566, 2014
Cyprus in crisis: recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment
P Petrou, S Vandoros
Health Policy 119 (5), 563-568, 2015
The system can't perform the operation now. Try again later.
Articles 1–20